Meridian Bioscience, Inc. (NASDAQ:VIVO) – Equities research analysts at Piper Jaffray Companies lowered their FY2019 earnings per share estimates for Meridian Bioscience in a report released on Tuesday, April 2nd. Piper Jaffray Companies analyst W. Quirk now anticipates that the company will post earnings per share of $0.65 for the year, down from their prior estimate of $0.77. Piper Jaffray Companies currently has a “Underweight” rating and a $15.00 price target on the stock. Piper Jaffray Companies also issued estimates for Meridian Bioscience’s FY2021 earnings at $0.77 EPS.
Other equities research analysts also recently issued research reports about the company. BidaskClub downgraded Meridian Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 15th. ValuEngine upgraded Meridian Bioscience from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Finally, Zacks Investment Research cut Meridian Bioscience from a “buy” rating to a “hold” rating and set a $19.00 price objective for the company. in a report on Saturday, January 19th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $14.75.
NASDAQ VIVO opened at $13.17 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.75 and a quick ratio of 4.72. The company has a market capitalization of $570.21 million, a PE ratio of 17.80 and a beta of 0.49. Meridian Bioscience has a 1-year low of $13.06 and a 1-year high of $19.84.
Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, January 24th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.02. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. The firm had revenue of $51.48 million for the quarter, compared to analyst estimates of $51.50 million. During the same quarter in the prior year, the business posted $0.15 EPS. The business’s revenue was down 1.5% compared to the same quarter last year.
Institutional investors have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund bought a new stake in shares of Meridian Bioscience during the 4th quarter worth approximately $280,000. Jefferies Group LLC purchased a new position in Meridian Bioscience in the 3rd quarter worth about $217,000. WINTON GROUP Ltd bought a new position in Meridian Bioscience during the 4th quarter valued at about $3,724,000. New York State Teachers Retirement System lifted its stake in Meridian Bioscience by 1.6% during the 4th quarter. New York State Teachers Retirement System now owns 132,502 shares of the company’s stock valued at $2,300,000 after acquiring an additional 2,100 shares during the period. Finally, Vanguard Group Inc boosted its holdings in shares of Meridian Bioscience by 2.2% during the 3rd quarter. Vanguard Group Inc now owns 4,347,959 shares of the company’s stock valued at $64,784,000 after acquiring an additional 94,180 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.